(Q34114592)

English

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

14

object named as

John C Byrd

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

8

object named as

Kristie A Blum

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jeffrey A Jones

1

object named as

Jeffrey A Jones

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael R Grever

13

object named as

Michael R Grever

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Leslie A Andritsos

5

object named as

Leslie Andritsos

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4

object named as

Mitch A Phelps

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Robert A Baiocchi

6

object named as

Robert Baiocchi

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

3

object named as

Ming Poi

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Pierluigi Porcu

12

object named as

Pierluigi Porcu

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

11

object named as

Sam Penza

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Amy S Rupert

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Don M Benson

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Beth Christian

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Joseph Flynn

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

19-24

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

The binding of flavopiridol to blood serum albumin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150545

5 July 2018

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23568

21 January 2018

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23568

21 January 2018

Identifiers

10.1002/AJH.23568

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34114592&oldid=1950271464"